Dr. Grosso

Dolores Grosso, DNP, CRNP

Contact Dr. Grosso

834 Chestnut Street
Suite 320
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome
  2. Relapsed Multiple Myeloma Presenting as Intracranial Plasmacytoma and Malignant Pericardial Effusion following Recent Allogeneic Stem Cell Transplantation
  3. Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization
  4. Evaluating frequency and quality of pathogen-specific T cells
  5. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  6. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  7. Immunotherapy in acute myeloid leukemia
  8. Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?
  9. Recent advances in haploidentical stem cell transplantation
  10. A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation
  11. Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host or Graft-versus-Graft Effects
  12. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  13. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  14. T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions
  15. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
  16. Cytoprotection in acute myelogenous leukemia (AML) therapy
  17. High complete remission rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML